Immunic (IMUX) EBITDA (2013 - 2026)

Immunic (IMUX) has 14 years of EBITDA data on file, last reported at -$33.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 23.9% year-over-year to -$33.2 million; the trailing twelve-month figure through Mar 2026 stood at -$109.6 million (down 8.56% YoY), and the FY2025 full-year result was -$103.2 million, down 5.28% from the prior year.
• EBITDA declined to -$33.2 million in Q1 2026, from -$23.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$20.1 million in Q3 2022 to a low of -$57.3 million in Q4 2022.
• A 5-year average of -$26.7 million and a median of -$25.0 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 163.92% in 2022 and jumped 59.21% in 2023, its largest moves.
• Tracing IMUX's EBITDA over 5 years: stood at -$57.3 million in 2022, then jumped by 59.21% to -$23.4 million in 2023, then declined by 9.62% to -$25.6 million in 2024, then grew by 8.99% to -$23.3 million in 2025, then tumbled by 42.47% to -$33.2 million in 2026.
• Business Quant data shows IMUX's EBITDA at -$33.2 million in Q1 2026, -$23.3 million in Q4 2025, and -$26.0 million in Q3 2025.